Skip to content

Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction

Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05986890
Enrollment
16
Registered
2023-08-14
Start date
2023-08-17
Completion date
2026-12-01
Last updated
2025-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Gastric Outlet Obstruction

Keywords

MGOO, Malignant gastric outlet obstruction, gastric outlet, malignant tumor, proximal bowel obstruction, bowel obstruction

Brief summary

This study is intended to investigate whether roux-en-y bypass surgery is superior to conventional loop gastrojejunostomy for Malignant gastric outlet obstruction in terms of tolerance to solid food intake. We hypothesize that roux-en-y bypass will be associated with improved solid food intake in the first 30 days after surgery.

Detailed description

Malignant gastric outlet obstruction is when malignant tumor growth obstructs the gastric outlet at the level of the distal stomach or duodenum, causing food intolerance with nausea and vomiting. Most often, this signifies advanced neoplastic disease with associated poor prognosis for patients. Restoring patients to oral intake is important for palliative purposes. The current standard of care in patients requiring long-term alleviation of symptoms (≥2 months) is performing a loop gastrojejunostomy. This involves creating an intestinal bypass to the site of obstruction in the duodenum or distal stomach. This procedure has long been criticized for its poor resultant function for patients, mainly due to poor tolerance to food intake that include frequent episodes of nausea and vomiting and inability to for solid food intake. The need for a durable solution to malignant gastric outlet obstruction that provides better tolerance to solid food intake is evident. The roux-en-y gastric bypass procedure has been performed for a variety of indications for decades, most commonly for weight loss but also with oncologic resections of the stomach in cases of gastric cancer. Laparoscopic roux-en-y gastric bypass (R-Y bypass) has become the standard for this procedure in experienced hands and has been found to be safe in the short- and long term. The long-term function after R-Y bypass is generally favorable across published literature. No studies exist to compare loop gastrojejunostomy to roux-en-y gastric bypass in patients with malignant gastric outlet obstruction.

Interventions

laparoscopic Roux-en-Y

surgical gastrojejunostomy

Sponsors

Corewell Health West
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female aged ≥18 years old. 4. Patients with a diagnosis of malignant gastric outlet obstruction. i. Defined as malignant cancer growth of any organ origin in the area of the distal stomach or duodenum preventing normal gastric emptying as determined by symptoms and cross-sectional imaging studies. ii. Symptoms can include abdominal distention, abdominal pain, nausea and vomiting. iii. Cross sectional imaging findings can include tumor growth in the area of the distal stomach or duodenum, gastric distention, fluid filled stomach and decompressed bowel distal to obstruction point. 5. Patients deemed to benefit from surgical bypass as opposed to stent placement, by the primary surgeon. This includes assessing participants survival chances and ability to undergo a surgical procedure. 6. Patients in a general health status that permits abdominal surgery under general anesthesia. As determined by primary surgeon and anesthesiologist.

Exclusion criteria

1. Patients that have had previous treatment for malignant gastric outlet obstruction. a. Including any previous surgery or stent placement for MGOO 2. Patients with MGOO deemed to benefit more from endoscopic stent placement rather than surgery for symptom relief. This assessment will be at treating surgeon's discretion.

Design outcomes

Primary

MeasureTime frameDescription
Gastric emptying as per gastric emptying scintigraphy at 7 days post-operatively.7 days post operativeResults of this study are given as percentage gastric emptying of radioactive (99mTc-SC) nutrients

Secondary

MeasureTime frameDescription
Patient reported daily gastric outlet obstruction scoring system (GOOS) score30 days postoperativePatients will score each day with the score that reflects the diet that was tolerated that day by the patient. This includes what was able to be ingested without a subsequent vomiting.
Number of Clavien-Dindo grade ≥3 adverse event14 days postoperative
Number of patients requiring reoperation for any indication30 days postoperative
Gastric emptying study at 30-days30 days post operativeResults of this study are given as percentage gastric emptying of radioactive (99mTc-SC) nutrients
Time from surgery to death100 days postoperative
Improvement of quality of life as measured by short form QOL Questionnairemeasured pre-operatively, at 25-35 days post op and 80-100 days post opThe short form 36 question QOL questionnaire results in a cumulative score with an increase in score representing a better health-related quality of life
Improvement of quality of life as measured GIQLImeasured pre-operatively, at 25-35 days post op and 80-100 days post opThe Gastrointestinal quality of life questionnaire results in a cumulative score with an increase in score representing a better health-related quality of life
number of patients with diagnoses of delayed gastric emptying defined as per the International Study Group of Pancreatic Surgery30 days postoperative

Countries

United States

Contacts

Primary ContactG. Paul Wright, MD
paul.wright@corewellhealth.org616-486-6333
Backup ContactCindy Cheung, BS
cindy.cheung@corewellhealth.org6164860990

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026